New schizophrenia drug VV119 enters first human safety tests

NCT ID NCT06504290

First seen Jan 07, 2026 · Last updated May 16, 2026 · Updated 23 times

Summary

This early-phase study tests the safety and tolerability of VV119 capsules in 40 people: first in healthy adults, then in patients with schizophrenia. Researchers will monitor side effects and measure drug levels in the blood. The goal is to gather initial safety data before larger trials.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SCHIZOPHRENIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Beijing Anding Hospital of Capital Medical University

    RECRUITING

    Beijing, Beijing Municipality, China

  • Beijing Anding Hospital of Capital Medical University

    RECRUITING

    Beijing, Beijing Municipality, China

    Contact

    Contact

  • Beijing Huilongguan Hospital

    RECRUITING

    Beijing, Beijing Municipality, China

    Contact

  • Xi'an Mental Health Center

    RECRUITING

    Xi’an, Shanxi, China

    Contact

Conditions

Explore the condition pages connected to this study.